Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study

Reuters2026/08/17 07:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dicot Pharma filed an EU clinical trial application for a phase 2b study of erectile-dysfunction candidate LIB-01.
Trial planned in the US, Europe; adaptive design with at least 200 participants to support dose selection for phase 3.
EU regulatory decision expected in Q4 2026; FDA cleared the first part of the phase 2b study in June 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dicot Pharma submits EU clinical trial application for LIB-01 phase 2b study

You may also like

Crypto prices